Severe asthma and quality of life

Elham Hossny, Luis Caraballo, Thomas Casale, Yehia El-Gamal, Lanny Rosenwasser, Elham Hossny, Luis Caraballo, Thomas Casale, Yehia El-Gamal, Lanny Rosenwasser

Abstract

Severe asthma has a great impact on the quality of life (QOL) of patients and their families. The magnitude of this morbidity is affected by several personal factors including age. Appropriate asthma control and modifications of social roles and activities are expected to improve QOL. Biologics, primarily monoclonal antibodies, have been developed to target specific pathways and molecules important in the pathogenesis of asthma. The use of biologics has shown some promising effects on the QOL of patients with severe recalcitrant asthma. Other potential measures involve targeting risk factors and comorbidities and improving the levels of adherence to therapy. This article briefly reviews the impact of severe asthma on QOL and the potential methods to combat this morbidity including the available therapeutic biologics.

Keywords: Adherence; Biologics; Monoclonal antibodies; Quality of life; Severe asthma.

Conflict of interest statement

Ethics approval and consent to participate

Not Applicable.

The manuscript does not report on or involve the use of any animal or human data or tissue.

Consent for publication

Not Applicable.

The manuscript does not contain any individual persons’ data.

Competing interests

The authors have no competing interests to declare relevant to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–9.
    1. Wilson SR, Rand CS, Cabana MD, Foggs MB, Halterman JS, Olson L, Vollmer WM, Wright RJ, Taggart V. Asthma outcomes: quality of life. J Allergy Clin Immunol. 2012;129(3 Suppl):S88–123. doi: 10.1016/j.jaci.2011.12.988.
    1. Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J. 2004;23(2):287–291. doi: 10.1183/09031936.04.00064204.
    1. Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544–552. doi: 10.1016/j.jaip.2014.02.011.
    1. Stucky BD, Sherbourne CD, Edelen MO, Eberhart NK. Understanding asthma-specific quality of life: moving beyond asthma symptoms and severity. Eur Respir J. 2015;46(3):680–687. doi: 10.1183/09031936.00225014.
    1. Moy ML, Israel E, Weiss ST, Juniper EF, Dubé L, Drazen JM, NHBLI Asthma Clinical Research Network Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med. 2001;163(4):924–929. doi: 10.1164/ajrccm.163.4.2008014.
    1. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83. doi: 10.1136/thx.47.2.76.
    1. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi: 10.1016/j.jaci.2003.09.008.
    1. Alpaydin AO, Bora M, Yorgancioglu A, Coskun AS, Celik P. Asthma control test and asthma quality of life questionnaire association in adults. Iran J Allergy Asthma Immunol. 2012;11(4):301–307.
    1. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5(1):35–46. doi: 10.1007/BF00435967.
    1. Hooi LN. What are the clinical factors that affect quality of life in adult asthmatics? Med J Malaysia. 2003;58(4):506–515.
    1. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–27. doi: 10.3132/pcrj.2007.00002.
    1. Riccioni G, D'Orazio N, Di Ilio C, Menna V, Guagnano MT, Della VR. Quality of Life and clinical symptoms in asthmatic subjects. J Asthma. 2004;41(1):85–89. doi: 10.1081/JAS-120026065.
    1. Avallone KM, McLeish AC, Luberto CM, Bernstein JA. Anxiety sensitivity, asthma control, and quality of life in adults with asthma. J Asthma. 2012;49(1):57–62. doi: 10.3109/02770903.2011.641048.
    1. Altiparmak S, Altiparmak O, Sari HY. Asthma and quality of life in adolescents in Manisa, Turkey. Int J Adolesc Med Health. 2011;23(3):217–221. doi: 10.1515/ijamh.2011.047.
    1. Sundell K, Bergström SE, Hedlin G, Ygge BM, Tunsäter A. Quality of life in adolescents with asthma, during the transition period from child to adult. Clin Respir J. 2011;5(4):195–202. doi: 10.1111/j.1752-699X.2010.00218.x.
    1. Matterne U, Schmitt J, Diepgen TL, Apfelbacher C. Children and adolescents’ health-related quality of life in relation to eczema, asthma and hay fever: results from a population-based cross-sectional study. Qual Life Res. 2011;20(8):1295–1305. doi: 10.1007/s11136-011-9868-9.
    1. Svavarsdottir EK, Burkhart PV, Rayens MK, Orlygsdottir B, Oakley MG. Icelandic and United States families of adolescents with asthma: predictors of health-related quality of life from the parents’ perspective. J Clin Nurs. 2011;20(1–2):267–273. doi: 10.1111/j.1365-2702.2009.03110.x.
    1. Van De Ven MO, Engels RC. Quality of life of adolescents with asthma: the role of personality, coping strategies, and symptom reporting. J Psychosom Res. 2011;71(3):166–173. doi: 10.1016/j.jpsychores.2011.03.002.
    1. Matsunaga NY, Ribeiro MA, Saad IA, Morcillo AM, Ribeiro JD, Toro AA. Evaluation of quality of life according to asthma control and asthma severity in children and adolescents. J Bras Pneumol. 2015;41(6):502–508. doi: 10.1590/s1806-37562015000000186.
    1. Goldbeck L, Koffmane K, Lecheler J, Thiessen K, Fegert JM. Disease severity, mental health, and quality of life of children and adolescents with asthma. Pediatr Pulmonol. 2007;42(1):15–22. doi: 10.1002/ppul.20509.
    1. Cerdan NS, Alpert PT, Moonie S, Cyrkiel D, Rue S. Asthma severity in children and the quality of life of their parents. Appl Nurs Res. 2012;25(3):131–137. doi: 10.1016/j.apnr.2011.01.002.
    1. Sawyer MG, Spurrier N, Whaites L, Kennedy D, Martin AJ, Baghurst P. The relationship between asthma severity, family functioning and the health-related quality of life of children with asthma. Qual Life Res. 2000;9(10):1105–1115. doi: 10.1023/A:1016655511879.
    1. Ungar WJ, Macdonald T, Cousins M. Better breathing or better living? A qualitative analysis of the impact of asthma medication acquisition on standard of living and quality of life in low-income families of children with asthma. J Pediatr Health Care. 2005;19(6):354–362. doi: 10.1016/j.pedhc.2005.06.004.
    1. Uchmanowicz B, Panaszek B, Uchmanowicz I, Rosińczuk J. Clinical factors affecting quality of life of patients with asthma. Patient Prefer Adherence. 2016;10:579–589. doi: 10.2147/PPA.S103043.
    1. Ekici A, Ekici M, Kara T, Keles H, Kocyigit P. Negative mood and quality of life in patients with asthma. Qual Life Res. 2006;15(1):49–56. doi: 10.1007/s11136-005-8869-y.
    1. Muraro A, Lemanske RF, Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, Jutel M, Ong PY, Poulsen LK, Schmid-Grendelmeier P, Simon HU, Seys SF, Agache I. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2016;137(5):1347–1358. doi: 10.1016/j.jaci.2016.03.010.
    1. Stokes JR, Casale TB. Characterization of asthma endotypes: implications for therapy. Ann Allergy Asthma Immunol. 2016;117(2):121–125. doi: 10.1016/j.anai.2016.05.016.
    1. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, Lin SL. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302. doi: 10.1164/rccm.201212-2318OC.
    1. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM, Stryszak P, Gann L, Sadeh J, Chanez P, Study Investigators Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–1103. doi: 10.1111/j.1365-2222.2012.04014.x.
    1. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi: 10.1164/rccm.201208-1414OC.
    1. Busse W, Spector S, Rosen K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485–486. doi: 10.1016/j.jaci.2013.02.032.
    1. Casale TB, Omachi TA, Trzaskoma B, Rao S, Chou W, Ortiz B, Manga V, Djukanovic R. Estimated asthma exacerbation reduction from omalizumab in a severe eosinophilic asthma population [abstract] J Allergy Clin Immunol. 2015;135(2):AB1. doi: 10.1016/j.jaci.2014.12.937.
    1. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P, MENSA Investigators Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi: 10.1056/NEJMoa1403290.
    1. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi: 10.1016/S0140-6736(12)60988-X.
    1. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG. Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi: 10.1056/NEJMoa1403291.
    1. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi: 10.1016/S2213-2600(15)00042-9.
    1. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810. doi: 10.1016/j.chest.2016.03.018.
    1. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–798. doi: 10.1016/j.chest.2016.03.032.
    1. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-27.
    1. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi: 10.1016/S0140-6736(16)31322-8.
    1. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–796. doi: 10.1016/S2213-2600(16)30265-X.
    1. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338. doi: 10.1183/09031936.00223411.
    1. Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, StreicherK RK, Piper E. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3(9):692–701. doi: 10.1016/S2213-2600(15)00197-6.
    1. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466. doi: 10.1056/NEJMoa1304048.
    1. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi: 10.1016/S0140-6736(16)30307-5.
    1. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD, Omalizumab 011 International Study Group Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632–638. doi: 10.1111/j.1365-2222.2004.1916.x.
    1. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi: 10.1111/j.1398-9995.2004.00772.x.
    1. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573–582. doi: 10.7326/0003-4819-154-9-201105030-00002.
    1. Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604–609. doi: 10.1136/archdischild-2011-301570.
    1. Barnes N, Menzies-Gow A, Mansur AH, Spencer D, Percival F, Radwan A, Niven R. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma. 2013;50(5):529–536. doi: 10.3109/02770903.2013.790419.
    1. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–1151. doi: 10.1016/j.rmed.2013.04.017.
    1. Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K, Doi S, Yamaguchi K, Katsunuma T, Kurihara K, Kondo N, Sugai K, Nambu M, Hoshioka A, Yoshihara S, Sato N, Seko N, Nishima S. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol Int. 2015;64(4):364–370. doi: 10.1016/j.alit.2015.05.006.
    1. Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M. Zhong N; China Omalizumab Study Group. Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study. Allergy Asthma Immunol Res. 2016;8(4):319–328. doi: 10.4168/aair.2016.8.4.319.
    1. Alhossan A, Lee CS, MacDonald K, Abraham I. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: Meta-analysis. J Allergy Clin Immunol Pract. 2017;25 [Epub ahead of print]
    1. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi: 10.1056/NEJMoa0808991.
    1. Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71(9):1335–1344. doi: 10.1111/all.12914.
    1. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi: 10.1016/S2213-2600(17)30125-X.
    1. Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–756. doi: 10.1136/thoraxjnl-2014-206719.
    1. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Updated April 2016. Available at: . Accessed 20 Nov 2016.
    1. Boyd M, Lasserson TJ, McKean MC, Gibson PG, Ducharme FM, Haby M. Interventions for educating children who are at risk of asthma related emergency department attendance. Cochrane Database Syst Rev. 2009;2:CD001290.
    1. Andrade WC, Camargos P, Lasmar L, Bousquet J. A pediatric asthma management program in a low-income setting resulting in reduced use of health service for acute asthma. Allergy. 2010;65(11):1472–1477. doi: 10.1111/j.1398-9995.2010.02405.x.
    1. McWhirter J, McCann D, Coleman H, Calvert M, Warner J. Can schools promote the health of children with asthma? Health Educ Res. 2008;23(6):917–930. doi: 10.1093/her/cym081.
    1. Beebe A, Gelfand EW, Bender B. A randomized trial to test the effectiveness of art therapy for children with asthma. J Allergy Clin Immunol. 2010;126(2):263–266. doi: 10.1016/j.jaci.2010.03.019.
    1. Garbutt JM, Banister C, Highstein G, Sterkel R, Epstein J, Bruns J, Swerczek L, Wells S, Waterman B, Strunk RC, Bloomberg GR. Telephone coaching for parents of children with asthma: Impact and lesson learned. Arch Pediatr Adolesc Med. 2010;164(7):625–630. doi: 10.1001/archpediatrics.2010.91.
    1. Garbutt JM, Sylvia S, Rook S, Schmandt M, Ruby-Ziegler C, Luby J, Strunk RC. Peer training to improve parenting and childhood asthma management skills: a pilot study. Ann Allergy Asthma Immunol. 2015;114(2):148–149. doi: 10.1016/j.anai.2014.10.023.
    1. Sawyer MG, Spurrier N, Kennedy D, Martin J. The relationship between the quality of life of children with asthma and family functioning. J Asthma. 2001;38(3):279–284. doi: 10.1081/JAS-100000115.
    1. Wells KE, Peterson EL, Ahmedani BK, Williams LK. Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol. 2013;111(3):216–220. doi: 10.1016/j.anai.2013.06.008.
    1. Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients. J Asthma. 2016;53(5):538–545. doi: 10.3109/02770903.2015.1116087.
    1. Luks V, Burkett A, Turner L, Pakhale S. Effect of physical training on airway inflammation in animal models of asthma: a systematic review. BMC Pulm Med. 2013;13:24. doi: 10.1186/1471-2466-13-24.
    1. Alberca-Custódio RW, Greiffo FR, MacKenzie B, Oliveira-Junior MC, Andrade-Sousa AS, Graudenz GS, Santos AB, Damaceno-Rodrigues NR, Castro-Faria-Neto HC, Arantes-Costa FM, Martins Mde A, Abbasi A, Lin CJ, Idzko M, Ligeiro Oliveira AP, Northoff H, Vieira RP. Aerobic exercise reduces asthma phenotype by modulation of the leukotriene pathway. Front Immunol. 2016;7:237. doi: 10.3389/fimmu.2016.00237.
    1. Manion AB, Velsor-Friedrich B. Quality of life and health outcomes in overweight and non-overweight children with asthma. J Pediatr Health Care. 2017;31(1):37–45. doi: 10.1016/j.pedhc.2016.01.005.
    1. Kalyva E, Eiser C, Papathanasiou A. Health-related quality of life of children with asthma: self and parental perceptions. Int J Behav Med. 2016;23(6):730–737. doi: 10.1007/s12529-016-9558-7.
    1. Kanemitsu Y, Niimi A, Matsumoto H, Iwata T, Ito I, Oguma T, Inoue H, Tajiri T, Nagasaki T, Izuhara Y, Petrova G, Birring SS, Mishima M. Gastroesophageal dysmotility is associated with the impairment of cough-specific quality of life in patients with cough variant asthma. Allergol Int. 2016;65(3):320–326. doi: 10.1016/j.alit.2016.02.014.
    1. Favreau H, Bacon SL, Labrecque M, Lavoie KL. Prospective impact of panic disorder and panic-anxiety on asthma control, health service use, and quality of life in adult patients with asthma over a 4-year follow-up. Psychosom Med. 2014;76(2):147–155. doi: 10.1097/PSY.0000000000000032.
    1. Krouse HJ, Yarandi H, McIntosh J, Cowen C, Selim V. Assessing sleep quality and daytime wakefulness in asthma using wrist actigraphy. J Asthma. 2008;45(5):389–395. doi: 10.1080/02770900801971800.
    1. Luyster FS, Teodorescu M, Bleecker E, Busse W, Calhoun W, Castro M, Chung KF, Erzurum S, Israel E, Strollo PJ, Wenzel SE. Sleep quality and asthma control and quality of life in non-severe and severe asthma. Sleep Breath. 2012;16(4):1129–1137. doi: 10.1007/s11325-011-0616-8.
    1. Schauer U, Bergmann KC, Gerstlauer M, Lehmann S, Gappa M, Brenneken A, Schulz C, Ahrens P, Schreiber J, Wittmann M, Hamelmann E, all members of the German Asthma Net (GAN). Improved asthma control in patients with severe, persistent allergic asthma after 12 months of nightly temperature-controlled laminar airflow: an observational study with retrospective comparisons. Eur Clin Respir J. 2015:2.
    1. Pretolani M, Bergqvist A, Thabut G, Dombret MC, Knapp D, Hamidi F, Alavoine L, Taillé C, Chanez P, Erjefält JS, Aubier M. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations. J Allergy Clin Immunol. 2016;5 [Epub ahead of print]
    1. Torrego A, Solà I, Munoz AM, Roqué I, Figuls M, Yepes-Nuñez JJ, Alonso-Coello P, Plaza V. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014;3:CD009910.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner